Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ABSK021 plus chemotherapy with or without toripalimab in advanced pancreatic cancer
CTR20233124Phase 2Terminated
- Sponsor
- Abbisko Therapeutics
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pimicotinib, toripalimab in pancreatic adenocarcinoma (PDAC), sponsored by Abbisko Therapeutics. Started Nov 2023; status: terminated.
02
Drugs
pimicotinibtoripalimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20233124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233124.